Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease

Documents similaires

• Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment
  par: Islam R. Younis, et autres
  Publié: (2024)
• Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment
  par: Raj Vuppalanchi, et autres
  Publié: (2024)
• Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
  par: Megumi Iwai, et autres
  Publié: (2025)
• Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib
  par: Martha Gonzalez, et autres
  Publié: (2025)
• Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
  par: Yan‐ou Yang, et autres
  Publié: (2025)